المؤلفون: Tsai, Katy K, Zarzoso, Inés, Daud, Adil I

المصدر: Human Vaccines & Immunotherapeutics. 10(11)

مصطلحات موضوعية: Cancer, Immunization, Climate-Related Exposures and Conditions, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, B7-H1 Antigen, CTLA-4 Antigen, Humans, Immunotherapy, Lymphocyte Activation, Melanoma, Nivolumab, Programmed Cell Death 1 Receptor, T-Lymphocytes, BMS-936559, PD-1, PD-L1, PD-L2, immunotherapy, MPDL3280A, melanoma, nivolumab, pembrolizumab, AE, adverse event, APC, antigen presenting cell, ASCO, American Society of Clinical Oncology, CTLA-4, cytotoxic T-lymphocyte-associated protein 4, FDA, Food and Drug Administration, gp100, glycoprotein 100 vaccine, Ig, immunoglobulin, ITIM, immunoreceptor tyrosine-based inhibitory motif, ITSM, immunoreceptor tyrosine-based switch motif, MAPK, mitogen-activated protein kinase, MHC, major histocompatibility complex, NK, natural killer, ORR, objective response rate, OS, overall survival, PD, progressive disease, programmed cell death 1, programmed cell death ligand 1, PFS, progression free survival, TCR, T cell receptor, TIL, tumor infiltrating lymphocyte, AE, adverse event, APC, antigen presenting cell, ASCO, American Society of Clinical Oncology, CTLA-4, cytotoxic T-lymphocyte-associated protein 4, FDA, Food and Drug Administration, ITIM, immunoreceptor tyrosine-based inhibitory motif, ITSM, immunoreceptor tyrosine-based switch motif, Ig, immunoglobulin, MAPK, mitogen-activated protein kinase, MHC, major histocompatibility complex, NK, natural killer, ORR, objective response rate, OS, overall survival, PD, progressive disease, PD-1, programmed cell death 1, PD-L1, programmed cell death ligand 1, PFS, progression free survival, TCR, T cell receptor, TIL, tumor infiltrating lymphocyte, gp100, glycoprotein 100 vaccine, Immunology, Medical Microbiology, Pharmacology and Pharmaceutical Sciences, Virology

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/49q8w2djTest

المؤلفون: Park, Ji-Eun, Kim, Seong-Eun, Keam, Bhumsuk, Park, Ha-Ram, Kim, Soyeon, Kim, Miso, Kim, Tae Min, Doh, Junsang, Kim, Dong-Wan, Heo, Dae Seog

المساهمون: 도준상, 김동완, 허대석, Doh, Junsang, Kim, Dong-Wan, Heo, Dae Seog

مصطلحات موضوعية: ACQUIRED-RESISTANCE, TUMOR-CELLS, POLYMORPHISMS, MECHANISM, MPDL3280A, THERAPY, CD107A, PD-L1, killer cells, natural, immunotherapy, cytotoxicity, immunological, lung neoplasms, head and neck neoplasms

العلاقة: Journal for ImmunoTherapy of Cancer, Vol.8 No.2, p. e000873; 113243; https://hdl.handle.net/10371/171814Test; 000573896000003; 2-s2.0-85089794266

الإتاحة: https://doi.org/10.1136/jitc-2020-000873Test
https://hdl.handle.net/10371/171814Test

المؤلفون: Aydin AM, Woldu SL, Hutchinson RC, Boegemann M, Bagrodia A, Lotan Y, Margulis V, Krabbe LM

المصدر: OncoTargets and Therapy, Vol Volume 10, Pp 1487-1502 (2017)

مصطلحات موضوعية: atezolizumab, MPDL3280A, bladder cancer, PD-L1, immunotherapy, metastatic, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/spotlight-on-atezolizumab-and-its-potential-in-the-treatment-of-advanc-peer-reviewed-article-OTTTest; https://doaj.org/toc/1178-6930Test

الوصول الحر: https://doaj.org/article/4dfe5936408945b9b45c32ce1eb52e41Test

المؤلفون: Sarah L Scarpace

المصدر: Drugs in Context, Pp 1-7 (2015)

مصطلحات موضوعية: carcinoma, squamous cell, non-small-cell lung cancer, immunotherapy, molecular targeted therapy, antibodies, monoclonal, nivolumab, pembrolizumab, cisplatin, carboplatin, gemcitabine, pemetrexed, ramucirumab, bevacizumab, programmed cell death-1 receptor, avelumab, MSB0010718C, MPDL3280A, MEDI4736, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: http://www.drugsincontext.com/metastatic-squamous-cell-non-small-cell-lung-cancer-nsclc-disrupting-the-drug-treatment-paradigm-with-immunotherapiesTest/; https://doaj.org/toc/1740-4398Test

الوصول الحر: https://doaj.org/article/266dccd9e1ff46f68d41602c2aa9441aTest

المؤلفون: Ali, HR, Dariush, A, Provenzano, E, Bardwell, H, Abraham, JE, Iddawela, M, Vallier, A-L, Hiller, L, Dunn, JA, Bowden, SJ, Hickish, T, McAdam, K, Houston, S, Irwin, MJ, Pharoah, PDP, Brenton, JD, Walton, NA, Earl, HM, Caldas, C

مصطلحات موضوعية: Science & Technology, Life Sciences & Biomedicine, Oncology, Breast cancer, Computational pathology, Neoadjuvant, Lymphocytes, Treatment resistance, Immunology, TUMOR-INFILTRATING LYMPHOCYTES, ANTHRACYCLINE CHEMOTHERAPY, PROTEIN EXPRESSION, AUTOMATED-ANALYSIS, SYSTEMS PATHOLOGY, NEO-TANGO, TRIAL, ASSOCIATION, PROGNOSIS, MPDL3280A, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Biopsy, Breast Neoplasms, Chemotherapy, Adjuvant, Epirubicin, Female

العلاقة: Breast Cancer Research; http://hdl.handle.net/10044/1/51078Test; https://dx.doi.org/10.1186/s13058-016-0682-8Test

الإتاحة: https://doi.org/10.1186/s13058-016-0682-8Test
http://hdl.handle.net/10044/1/51078Test

المؤلفون: Yair Lotan, Vitaly Margulis, Aditya Bagrodia, Solomon L. Woldu, Laura Maria Krabbe, Ahmet M. Aydin, Martin Boegemann, Ryan Hutchinson

المصدر: OncoTargets and therapy

مصطلحات موضوعية: atezolizumab, 0301 basic medicine, Oncology, medicine.medical_specialty, Metastatic Urothelial Carcinoma, medicine.medical_treatment, Context (language use), Review, Malignancy, 03 medical and health sciences, 0302 clinical medicine, Atezolizumab, PDL1, Internal medicine, medicine, Pharmacology (medical), Chemotherapy, Bladder cancer, business.industry, Immunotherapy, medicine.disease, metastatic, 030104 developmental biology, MPDL3280A, Tolerability, 030220 oncology & carcinogenesis, bladder cancer, immunotherapy, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2c24b0b19c02c3fddf74b04427923c6Test
https://doi.org/10.2147/ott.s109453Test

المؤلفون: Katarzyna Guzik, Przemyslaw Grudnik, Bartosz J. Zieba, Krzysztof M. Zak, Grzegorz Dubin, Bogdan Musielak, Alexander Dömling, Tad A. Holak

المساهمون: Drug Design, Medicinal Chemistry and Bioanalysis (MCB)

المصدر: Oncotarget
Oncotarget, 7(21), 30323-30335. Impact Journals LLC

مصطلحات موضوعية: Models, Molecular, 0301 basic medicine, Magnetic Resonance Spectroscopy, CLINICAL ACTIVITY, Programmed Cell Death 1 Receptor, drug protein binding, Plasma protein binding, ANTI-PD-L1 ANTIBODY, Pharmacology, Crystallography, X-Ray, drug research, THERAPY, B7-H1 Antigen, PROTEIN-PROTEIN INTERACTIONS, 0302 clinical medicine, Checkpoint inhibitor, binding affinity, conformational transition, Molecular Structure, Drug discovery, Chemistry, CHECKPOINT BLOCKADE, article, Ligand (biochemistry), Small molecule, unclassified drug, bms 8, Oncology, protein stability, MPDL3280A, 030220 oncology & carcinogenesis, protein protein interaction, CANCER-IMMUNOTHERAPY, immunotherapy, Immunotherapy, drug potency, Protein Binding, Signal Transduction, Research Paper, crystal structure, bms 37, medicine.drug_class, small molecule, Monoclonal antibody, Protein–protein interaction, Small Molecule Libraries, 03 medical and health sciences, Protein Domains, complex formation, inhibition kinetics, medicine, Humans, controlled study, human, nuclear magnetic resonance spectroscopy, STABILITY, drug targeting, bms 202, programmed death 1 receptor, molecular dynamics, NMR, programmed death 1 ligand 1, drug structure, checkpoint inhibitor, 030104 developmental biology, Targeted drug delivery, protein inhibitor, Biophysics, bms 242, drug synthesis, X-ray structure, INHIBITORS

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4077c489c1a3e54f918f43d3ca7d076cTest
https://hdl.handle.net/11370/66b38ebe-19cb-4ca3-bd38-d873a99853beTest

المؤلفون: Jedd D. Wolchok, David B. Page, Jarushka Naidoo

المصدر: British Journal of Cancer

مصطلحات موضوعية: Cancer Research, anti-PD-L1, medicine.medical_treatment, Ipilimumab, Immune system, tremelimumab, Antigen, Neoplasms, medicine, Humans, Antibody-dependent cell-mediated cytotoxicity, nivolumab, anti-CTLA4, business.industry, Immunotherapy, BMS-936559, Immune checkpoint, Oncology, MPDL3280A, Immunology, anti-PD-1, Minireview, Nivolumab, business, Tremelimumab, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23d6166bdfa37af6284efa3ef85ad2b5Test
http://europepmc.org/articles/PMC4264429Test

المؤلفون: Scheel, Andreas H., Ansen, Sascha, Schultheis, Anne M., Scheffler, Matthias, Fischer, Rieke N., Michels, Sebastian, Hellmich, Martin, George, Julie, Zander, Thomas, Brockmann, Michael, Stoelben, Erich, Groen, Harry, Timens, Wim, Perner, Sven, von Bergwelt-Baildon, Michael, Buettner, Reinhard, Wolf, Juergen

المصدر: Scheel , A H , Ansen , S , Schultheis , A M , Scheffler , M , Fischer , R N , Michels , S , Hellmich , M , George , J , Zander , T , Brockmann , M , Stoelben , E , Groen , H , Timens , W , Perner , S , von Bergwelt-Baildon , M , Buettner , R & Wolf , J 2016 , ' PD-L1 expression in non-small cell lung cancer : Correlations with genetic alterations ' , OncoImmunology , vol. 5 , no. 5 , 1131379 . https://doi.org/10.1080/2162402X.2015.1131379Test

مصطلحات موضوعية: Checkpoint inhibition, early stage NSCLC, genetic alterations, immunohistochemistry, non-small cell lung cancer, PD-L1, 5H1, DEATH-LIGAND 1, ANTIBODY MPDL3280A, BREAST-CANCER, NIVOLUMAB, MELANOMA, IMMUNE, TUMOR, B7-H1, ADENOCARCINOMA, PEMBROLIZUMAB

العلاقة: https://research.rug.nl/en/publications/45183bcf-9331-4a75-bb12-06f86907305bTest

الإتاحة: https://doi.org/10.1080/2162402X.2015.1131379Test
https://hdl.handle.net/11370/45183bcf-9331-4a75-bb12-06f86907305bTest
https://research.rug.nl/en/publications/45183bcf-9331-4a75-bb12-06f86907305bTest

المؤلفون: Li, Zhongwu, Lai, Yumei, Sun, Li, Zhang, Xiaotian, Liu, Ruping, Feng, Guoshuang, Zhou, Lixin, Jia, Lin, Huang, Xiaozheng, Kang, Wang, Lin, Dongmei, Gao, Jing, Shen, Lin

المساهمون: Gao, J, Shen, L (reprint author), Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, 52 Fucheng Rd, Beijing 100142, Peoples R China., Peking Univ Canc Hosp & Inst, Dept Pathol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing 100142, Peoples R China., Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing 100142, Peoples R China., Beijing Inst Graph Commun, Beijing 102600, Peoples R China., Capital Med Univ, Beijing Childrens Hosp, Ctr Clin Epidemiol & Evidence Based Med, Beijing 100045, Peoples R China., Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, 52 Fucheng Rd, Beijing 100142, Peoples R China.

المصدر: SCI ; PubMed

مصطلحات موضوعية: PD-Ll, EBV, Gastric cancer, Prognosis, HER2, EPSTEIN-BARR-VIRUS, ANTI-PD-L1 ANTIBODY, CARCINOMA, MPDL3280A, THERAPY, GENES, CELLS

العلاقة: HUMAN PATHOLOGY.2016,55,182-189.; 1389308; http://hdl.handle.net/20.500.11897/433470Test; WOS:000381541300024

الإتاحة: https://doi.org/20.500.11897/433470Test
https://doi.org/10.1016/j.humpath.2016.05.012Test
https://hdl.handle.net/20.500.11897/433470Test